Alzheimer's Disease

51 competing products in clinical development for Alzheimer's Disease.

Pipeline by Phase

Pre-clinical6

Phase 111

Phase 210

Phase 2/32

Phase 312

Approved10

All Products (51)

Product	Company	Stage	Status	Hype
Remternetug + Placebo	Eli Lilly	Phase 3	Active	44
lecanemab	Eisai	Phase 3	Active	44
Donepezil	Eisai	Approved	Completed	43
Donepezil HCL	Eisai	Approved	Completed	43
Donepezil Hydrochloride	Eisai	Approved	Completed	43
Aricept	Eisai	Approved	Completed	43
Donepezil	Eisai	Approved	Completed	43
Donepezil hydrochloride	Eisai	Approved	Completed	43
Experimental 1 + Placebo Comparator	Eisai	Approved	Completed	43
Rivastigmine transdermal patch	Ono Pharmaceutical	Approved	Completed	43
E2814 + Lecanemab + Matching Placebo (E2814)	Eisai	Phase 2/3	Active	42
Gantenerumab + Solanezumab + Matching Placebo (Gantenerumab) + Matching Placebo (Solanezumab) + Gantenerumab + E2814 + Lecanemab + Matching Placebo (E2814)	Eisai	Phase 2/3	Active	42
LY450139 + Placebo	Eli Lilly	Phase 3	Completed	40
Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg)	Eisai	Phase 3	Completed	40
Donepezil hydrochloride	Eisai	Phase 3	Completed	40
Donepezil	Eisai	Phase 3	Completed	40
donepezil	Eisai	Phase 3	Completed	40
Rivastigmine transdermal patch + Placebo	Ono Pharmaceutical	Phase 3	Completed	40
Active Comparator + ENA713	Ono Pharmaceutical	Phase 3	Completed	40
Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.	Yuhan	Approved	UNKNOWN	39
E2814 + Lecanemab + Placebo	Eisai	Phase 2	Active	39
LY450139 dihydrate + placebo	Eli Lilly	Phase 2	Completed	35
solanezumab	Eli Lilly	Phase 2	Completed	35
DONEPEZIL HYDROCHLORIDE	Eisai	Approved	Terminated	35
Lecanemab 2.5 mg/kg + Lecanemab 5.0 mg/kg + Lecanemab 10 mg/kg + Lecanemab 5.0 mg/kg + Lecanemab 10 mg/kg + Placebo + Lecanemab 10 mg/kg	Eisai	Phase 2	Completed	35
ONO-2506PO	Ono Pharmaceutical	Phase 2	Completed	35
Solanezumab + Placebo	Eli Lilly	Phase 3	Terminated	32
GSK4527226	Alector	Phase 2	Recruiting	32
Solanezumab + Placebo	Eli Lilly	Phase 3	Terminated	32
Elenbecestat + Placebo	Eisai	Phase 3	Terminated	32
GSK4527226	Alector	Phase 2	Active	29
LY2886721 + Placebo	Eli Lilly	Phase 1	Completed	29
Gantenerumab + Gantenerumab + Gantenerumab + Placebo	Chugai Pharmaceutical	Phase 1	Completed	29
ASP0777 + Placebo	Astellas Pharma	Phase 1	Completed	29
BAN2401 2.5 mg/kg + BAN2401 5 mg/kg + BAN2401 10 mg/kg + Placebo	Eisai	Phase 1	Completed	29
E2212 + placebo	Eisai	Phase 1	Completed	29
E2609 + Placebo for E2609	Eisai	Phase 1	Completed	29
Active Comparator: A + Placebo Comparator B + Active Comparator B + Placebo Comparator A	Eisai	Phase 1	Completed	29
E2609	Eisai	Phase 1	Completed	29
Drug: E2609 + Placebo	Eisai	Phase 1	Completed	29
KHK6640 + Matching Placebo	Kyowa Kirin	Phase 1	Completed	29
KHK6640 + Placebo	Kyowa Kirin	Phase 1	Completed	29
FK962	Astellas Pharma	Phase 2	Terminated	27
Donepezil Hydrochloride	Eisai	Pre-clinical	Completed	26
donepezil	Eisai	Pre-clinical	Completed	26
donepezil	Eisai	Pre-clinical	Completed	26
donepezil hydrochloride	Eisai	Pre-clinical	Completed	26
Aricept	Eisai	Pre-clinical	Completed	26
donepezil hydrochloride	Eisai	Pre-clinical	Completed	26
AL002	Alector	Phase 2	Terminated	17
simufilam	Cassava Sciences	Phase 2	Terminated	17